Phio Pharmaceuticals
PHIO
9 hedge funds and large institutions have $827K invested in Phio Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 0 reducing their positions, and 5 closing their positions.
279% more capital invested
Capital invested by funds: $218K → $827K (+$609K)
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
13% more funds holding
Funds holding: 8 → 9 (+1)
0.03% more ownership
Funds ownership: 0.02% → 0.05% (+0.03%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$188K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$172K |
| 3 |
Two Sigma Advisers
New York
|
+$158K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
+$58.9K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$47.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$77K |
| 2 |
Renaissance Technologies
New York
|
-$43K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$26K |
| 4 |
HSBC Holdings
London,
United Kingdom
|
-$24K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GCP
1
GSA Capital Partners
London,
United Kingdom
| $273K | +$188K | +742 | +377% |
|
|
2
Vanguard Group
Malvern,
Pennsylvania
| $198K | +$172K | +680 | New |
|
|
3
Two Sigma Advisers
New York
| $182K | +$158K | +627 | New |
|
|
4
Dimensional Fund Advisors
Austin,
Texas
| $68K | +$58.9K | +233 | New |
|
|
5
Geode Capital Management
Boston,
Massachusetts
| $54K | +$47.5K | +188 | New |
|
6
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $32K | +$28.3K | +112 | New |
|
7
UBS Group
Zurich,
Switzerland
| $15K | +$11.9K | +47 | +940% |
|
8
Morgan Stanley
New York
| $4K | +$3.54K | +14 | New |
|
9
JP Morgan Chase
New York
| $1K | – | – | – |
|
|
VF
10
Virtu Financial
New York
| – | -$77K | -333 | Closed |
|
|
11
Renaissance Technologies
New York
| – | -$43K | -188 | Closed |
|
|
12
Citadel Advisors
Miami,
Florida
| – | -$26K | -113 | Closed |
|
|
13
HSBC Holdings
London,
United Kingdom
| – | -$24K | -105 | Closed |
|
|
TRCT
14
Tower Research Capital (TRC)
New York
| – | -$1K | -5 | Closed |
|
PHIO Hedge Fund Activity: Q4 2020 in Review
9 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Phio Pharmaceuticals (PHIO) for Q4 2020, worth a combined $827K — up 279% from $218K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new PHIO positions and 5 closed out — a net gain of 1 holder — while 2 added to existing stakes and 0 trimmed.
The largest buyer was GSA Capital Partners, adding an estimated $188K. The largest seller was Virtu Financial, exiting entirely with an estimated $77K sold.
- 9 institutional investors held Phio Pharmaceuticals (PHIO) as of Q4 2020, up from 8 in Q3 2020.
- Funds reported $827K of Phio Pharmaceuticals stock for Q4 2020, up 279% quarter-over-quarter.
- 6 funds opened new Phio Pharmaceuticals positions in Q4 2020 and 5 closed out, a net change of +1 holder.
- The largest Phio Pharmaceuticals buyer in Q4 2020 was GSA Capital Partners, an estimated $188K added.
- The largest Phio Pharmaceuticals seller in Q4 2020 was Virtu Financial, an estimated $77K sold.
Based on aggregated 13F filings for Q4 2020.